PTC Therapeutics plans ST-920 Fabry program acquisition
PTC Therapeutics says it will acquire Sangamo Therapeutics’ ST-920 Fabry disease program in a competitive bankruptcy auction for $111 million upfront plus up to $100 million in contingent milestone payments.